Highest-materiality recent filing
Sarepta shareholders approve 2026 equity plans; elect directors at annual meeting
2026 Equity Incentive Plan approved: 63.2M for, 4.4M against; 6,286,841 shares reserved.
Sarepta Q1 GAAP EPS $2.88 vs loss of $4.60; siRNA pipeline shows early positive data
Net product revenue $330.5M (ELEVIDYS $102.0M, PMO $228.6M); total rev $730.8M (-2% YoY).
Sarepta reports Q4 2025 net loss of $412.2M; full-year revenue up 16% to $2.2B
Full-year 2025 net product revenue $1,864.3M (PMO $965.6M, ELEVIDYS $898.7M); Q4 net product revenue $369.6M.
Sarepta CEO Douglas Ingram to retire by end of 2026; successor search underway
CEO Douglas Ingram notified retirement by end of 2026 or upon appointment of replacement.
Sarepta preliminary 2025 net product revenue $1.86B; ELEVIDYS $898.7M
Total net product revenue Q4 $369.6M, full-year $1.86B; cash and investments $953.8M at year-end.
Sarepta exchanges $291.4M of 1.25% notes for 4.875% notes due 2030 plus $31.6M cash
Exchanged ~$291.4M of existing 1.25% Convertible Senior Notes due 2027 for new 4.875% Convertible Notes due 2030 plus ~$31.6M cash.
Sarepta exchanges $291M of 1.25% notes due 2027 for 4.875% notes due 2030 plus $31.6M cash
Exchanges $291.4M principal of 1.25% convertibles due 2027 for same principal of 4.875% convertibles due 2030, plus $31.6M in cash.
Sarepta grants CEO Ingram $12M equity awards after 8-year gap
CEO Douglas Ingram granted ~$12M total equity: ~$6M time-based RSUs vesting over 3 years and ~$6M performance-based awards tied to Incentive EBITDA for 2026-2027.
Sarepta reports Q3 GAAP net loss; ESSENCE confirmatory study misses primary endpoint
ESSENCE study did not meet primary endpoint (p=0.309); COVID-adjusted analysis showed trend (p=0.09).
Sarepta exchanges $700M convertible notes for $602M new 4.875% notes due 2030 plus stock and cash
Exchanged $700M of 1.25% Convertible Notes due 2027 for $602M of 4.875% Convertible Notes due 2030, 5.85M common shares, and ~$123.3M cash.
Sarepta exchanges $700M of 1.25% notes due 2027 for new 4.875% notes due 2030, stock, and cash
Exchanged ~$700M existing 1.25% convertible notes for $602M new 4.875% notes due 2030, $110M stock, and ~$123.3M cash.
Bilal Arif's employment ends Sept 16, 2025; served as EVP, Chief Technical Operations Officer until Aug 12.
FDA places clinical hold on Sarepta's LGMD gene therapy trials; revokes AAVrh74 platform designation
FDA placed clinical hold on LGMD trials for SRP-9003, SRP-9004, SRP-6004, and SRP-9005.
Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning
Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.
Sarepta shareholders approve 4.3M share increase to 2018 equity plan, 0.3M to ESPP
Vote approves adding 4,300,000 shares to 2018 Equity Incentive Plan (total now 17,487,596).
Sarepta Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS $384.2M; GAAP net income $159M
Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS contributed $384.2M; royalty from Roche $4.9M.
Sarepta enters $600M senior secured revolving credit facility with JPMorgan as admin agent
Five-year $600M revolving credit facility closed Feb 13, 2025; variable interest at Adjusted SOFR + 1.125%-1.75% spread based on leverage.
Preliminary total net product revenue Q4 2024 $638.2M, FY2024 $1.79B, exceeding full-year guidance by over $100M.
Sarepta enters $500M upfront license deal with Arrowhead for siRNA therapies; GC resigns
$500M upfront cash to Arrowhead; up to $300M near-term payments; up to $180M per program development milestones, $700M per program sales milestones; tiered royalties up to low double digits.
Sarepta appoints Deirdre Connelly to board, increases board size to 9
Deirdre Connelly appointed as Class I director effective Sept. 12, 2024, term through 2026 annual meeting.
Sarepta increases incentive plan shares by 500,000; all director nominees elected at annual meeting
Board approved amendment to 2024 Employment Commencement Incentive Plan, increasing share reserve by 500,000 to 6,185,308 shares.
Sarepta prelim FY2023 net product rev $1.145B; ELEVIDYS $200.4M beats consensus
Preliminary FY2023 total net product revenue of ~$1.145B; RNA PMOs $945.0M (above $925M guidance).
FDA grants accelerated approval for Sarepta's ELEVIDYS gene therapy for Duchenne MD
First FDA-approved gene therapy for Duchenne muscular dystrophy; for ambulatory patients aged 4-5.
Sarepta sets wholesale acquisition cost for ELEVIDYS at $3.2 million
Wholesale acquisition cost (gross price) of gene therapy ELEVIDYS set at $3.2 million.
Sarepta shareholders reject executive compensation in advisory vote; approve equity plan amendments
Advisory vote on 2022 named executive officer compensation failed: 52.8M against vs 20.4M for.
Sarepta exchanges $313.5M of 1.50% convertible notes due 2024 for common stock
Approximately $313.5M aggregate principal of 1.50% Convertible Senior Notes due 2024 exchanged for shares of common stock.
Sarepta prelim Q4 revenue $235.5M, FY $843.3M, exceeding guidance
Preliminary Q4 2022 net product revenue ~$235.5M, up 32% YoY.
Sarepta amends bylaws for universal proxy rules and DGCL updates
Board approved Second Amended and Restated Bylaws, effective December 9, 2022.
Sarepta EVP Technical Ops resigns, Bilal Arif appointed as replacement
William F. Ciambrone to resign as EVP Technical Operations effective Dec 31, 2022.
Sarepta Therapeutics issues $1.13B in convertible notes, repays $585.5M term loan
Issued $1.13B aggregate principal of 1.25% Convertible Senior Notes due 2027 to initial purchasers including Goldman Sachs and J.P. Morgan.
Sarepta shareholders approve 2.5M share increase to 2018 equity plan
Shareholders approved 2018 Plan Amendment, increasing authorized shares by 2.5M to 10,687,596.
Sarepta amends CEO Ingram's stock option; 33% vests immediately; new targets to 2025
33.33% (1,099,890 shares) of performance option vested effective April 19, 2022; remainder eligible through June 26, 2025.
Sarepta director Mary Ann Gray to not stand for re-election at 2022 annual meeting
Dr. Gray informed the Board on March 31, 2022, of her decision to complete her term at the 2022 annual meeting.
Preliminary FY2021 revenue $612M, Q4 revenue $178.7M from DMD therapies; cash $2.1B at year-end.
Sarepta appoints Stephen Mayo to board, promotes Rodino-Klapac to R&D head, O'Neill departs
Stephen L. Mayo appointed to Sarepta board, effective Nov 16, 2021; receives $712,500 equity grant split between RSUs and options plus $50k annual cash.
Sarepta prices $500M common stock offering; preliminary Q3 revenue up 37% to $166.9M
Preliminary Q3 2021 net product revenue of ~$166.9M, up from $121.4M in Q3 2020.
Sarepta to initiate pivotal Part B of MOMENTUM study for SRP-5051 in DMD patients
Positive FDA interactions enable early start of Part B of MOMENTUM study for SRP-5051.
Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.
Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.
On September 12, 2024, the board of directors (the “ Board ”) of Sarepta Therapeutics, Inc. (the “ Company ”) appointed Deirdre Connelly as a director of the Company, effective immediately, to serve as a member of Class I until the 2026 annual meeting of stockholders.
On October 31, 2022, the Board appointed Bilal Arif, the Company’s Senior Vice President, Strategy and Operations, as the Company’s Chief Technical Operations Officer, effective as of December 31, 2022 and upon Mr. Ciambrone’s retirement.
On October 31, 2022, William F. Ciambrone informed Sarepta Therapeutics, Inc. (the “Company”) of his resignation from his position as the Company’s Executive Vice President, Technical Operations, effective as of December 31, 2022.
Mary Ann Gray, Ph.D., informed the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) that she has elected to not stand for re-election and will complete her term on the Board at the conclusion of the Company’s 2022 annual meeting of stockholders.
On November 15, 2021, the Company and Gilmore O’Neill, M.B., M.M.Sc. mutually agreed to end Dr. O'Neill's employment with the Company, effective as of November 30, 2021
On November 16, 2021, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the "Company") appointed Stephen L. Mayo, Ph.D. as a director of the Company, effective as of November 16, 2021.
On November 16, 2021, Louise Rodino-Klapac, Ph.D., the Company's Chief Scientific Officer, was promoted to Head of R&D, Chief Scientific Officer.
Max materiality 1.00 · Median 0.70 · Most common event other_material